Nippon Express to provide global pharmaceutical supply networks
The company is already constructing a digital platform for the pharmaceutical industry that will utilize IoT devices and blockchain technology to link temperature control and other logistics information end-to-end.
Nippon Express is in the process of developing pharmaceutical supply chain networks that meet both hardware and software requirements for Good Distribution Practices (GDP) to enable safer and more secure supply of pharmaceuticals.
In view of the globalization of pharmaceutical supply chains, the company will also be setting up GDP-compliant business locations in major markets worldwide to enhance its supply networks on a global level.
Nippon Express is currently setting up pharmaceutical-specific facilities in East Japan, West Japan, Kyushu and Toyama to complement the 'medical hubs' of Narita International Airport and Kansai International Airport, which have long been involved in the import/export of raw materials and finished products.
These facilities will be equipped to handle GDP-compliant quality control and business continuity plans pertaining to pharmaceutical supply, and platforms will be constructed to allow for joint warehouse storage and transport, operations heretofore carried out on an individual customer basis, to cope with the shortages of truck drivers stemming from the round use of vehicles, and to achieve greater operational efficiency. These facilities will go into service in February 2021.
More specifically, the company is building GDP-compliant CFS at key pharmaceutical business locations overseas. It has already opened GDP-certified CFS in London and Milan, which both host clusters of manufacturers of new drugs, as well as in India, where generics are driving robust market growth; in the US, GDP certification was acquired in Chicago.
In addition to enhancing business locations in Europe and the US, Nippon Express is planning to obtain GDP certification in Asian countries where medical services are becoming more widely accessible.
Furthermore, Nippon Express will be looking to employ the digital technologies of IoT (Internet of Things) and blockchain to track logistics information end-to-end, to optimize supply chains for the industry as a whole via a data-driven approach that offers traceability and increased operational efficiency.
To ensure it has in place the extensive expertise and strict quality control required for pharmaceutical logistics, Nippon Express created a Pharmaceuticals Business Division and a Pharmaceuticals Logistics Quality Assurance Office in July 2020 to establish uniform group-wide standards on, for example, operational frameworks, human resource development, quality assurance regimes.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance